South San Francisco, United States
ESCAPE Bio, founded in 2015, is positioning itself as a transformative force in the Biotechnology and Health Care sectors. Based in the United States, this clinical-stage company focuses on a genetically defined approach to combat neurodegenerative diseases.
With the slogan, A CLINICAL-STAGE COMPANY DEVELOPING NOVEL, PRECISELY TARGETED THERAPIES FOR GENETIC NEURODEGENERATIVE DISEASES, the company is committed to making significant strides in therapies targeting CNS diseases. Their innovation is buoyed by substantial financial backing, highlighted by a $73.00M Series B investment on 14 September 2020.
Key investors include industry leaders such as Novo Holdings, Novartis Venture Fund, OrbiMed, Sutter Hill Ventures, Wellington Management, Rock Springs Capital, New Leaf Ventures, Sphera Funds Management, OUP (Osage University Partners), and Johnson & Johnson Innovation – JJDC.
For potential investors, ESCAPE Bio presents a promising opportunity within the realm of targeted disease-modification therapies.
